| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 78.5 | ¤929,545 | US |
| JNJ | Johnson & Johnson | 51.9 | ¤540,710 | US |
| AZN | AstraZeneca PLC | 64.2 | ¤286,784 | GB |
| MRK | Merck & Co., Inc. | 63.7 | ¤280,473 | US |
| AMGN | Amgen Inc. | 62.2 | ¤178,703 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| THC | Tenet Healthcare Corporation | 67.1 | ¤16,755 | US |
| DGX | Quest Diagnostics Incorporated | 55.4 | ¤20,936 | US |
| STE | STERIS plc | 59.3 | ¤21,033 | IE |
| DXCM | DexCom, Inc. | 77.6 | ¤23,291 | US |
| UTHR | United Therapeutics Corporation | 70.5 | ¤26,155 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 62.2 | 32 | US |
| LLY | Eli Lilly and Company | 78.5 | 27 | US |
| PFE | Pfizer Inc. | 50.9 | 25 | US |
| DGX | Quest Diagnostics Incorporated | 55.4 | 23 | US |
| ZTS | Zoetis, Inc. Class A | 63.7 | 23 | US |
| BMY | Bristol-Myers Squibb Company | 61.9 | 22 | US |
| JNJ | Johnson & Johnson | 51.9 | 22 | US |
| RMD | ResMed Inc. | 67.4 | 20 | US |
| GILD | Gilead Sciences, Inc. | 71.0 | 19 | US |
| UTHR | United Therapeutics Corporation | 70.5 | 18 | US |
| Average Market Cap | ¤128,859 |
| Median Market Cap | ¤47,968 |
| Avg. 3 Mo. Dollar Vol. | ¤640,002,579 |
| Avg. 3 Mo. Trading Vol. | 4,498,122 |
| Last Rebalance Date | 03/23/2026 |
| Companies Replaced | 7 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 23.5 |
| Forward P/E Ratio (12 Mo.) | 17.3 |
| Price/Book Ratio | 4.9 |
| Avg. Revenue Chg. - 3 Yr | 21.8% |
| Avg. Op. Income Chg. - 3 Yr. | 33.1% |
| Avg. EPS Growth - 3 Yr. | 13.4% |
| Avg. EPS Growth - 1 Yr. | 11.8% |
| Avg. Operating Margin | 23.2% |
| Avg. LT Debt to Total Capital | 41.7% |
| Avg. Return on Equity | 22.7% |
| Dividend Yield | 0.6% |
| US Health Care Index | 60.06 |
| United States Of America | 90.0% |
| Switzerland | 3.33% |
| United Kingdom | 3.33% |
| Ireland | 3.33% |
